Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy

Table 1 Plasma pharmacokinetic (PK) parameters following a single IP injection of 1.75 mg/kg TfRMAb-TNFR or 0.875 mg/kg etanercept, and following chronic IP injection of 1.75 mg/kg TfRMAb-TNFR (a single 1.75 mg/kg TfRMAb-TNFR injection after chronic 4-week treatment with saline or 1.75 mg/kg TfRMAb-TNFR)

Route	Group	Dose	Dosing frequency	AUC_(0–24 h)	C_max	AUC_(0–∞)
Route	Group	mg/kg	Dosing frequency	µg min/mL	µg/mL	µg min/mL
	Single injection PK
IP	TfRMAb-TNFR	1.75	Once	864 ± 46	1.6 ± 0.08	875 ± 45
	Etanercept	0.875	Once	7947 ± 664****	10.2 ± 1.3***	11,056 ± 843****
	Chronic dosing PK
	TfRMAb-TNFR (single injection)	1.75	Once at the end of 4 weeks	1705 ± 157	1.8 ± 0.3	6114 ± 1268
	TfRMAb-TNFR (chronic injection)	1.75	3 days per week for 4 weeks	2352 ± 280	2.4 ± 0.2	6960 ± 2033

Data are shown as the mean ± SEM (n = 4–6 mice per treatment group per time point). Two-sample t test was used to compare PK parameters
***p < 0.001, ****p < 0.0001 compared to TfRMAb-TNFR for the single injection PK study.

ISSN: 1742-2094